{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:55:25Z","timestamp":1760550925652},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40123-019-00209-w","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T20:03:40Z","timestamp":1568145820000},"page":"635-641","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant \u2013 A Case Report"],"prefix":"10.1007","volume":"8","author":[{"given":"Jorge","family":"Meira","sequence":"first","affiliation":[]},{"given":"Carolina","family":"Madeira","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Falc\u00e3o-Reis","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Figueira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"issue":"1","key":"209_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","volume":"26","author":"T Tsirouki","year":"2018","unstructured":"Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2\u201316.","journal-title":"Ocul Immunol Inflamm."},{"issue":"1","key":"209_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s40135-016-0090-3","volume":"4","author":"R Goldhardt","year":"2016","unstructured":"Goldhardt R, Rosen BS. Uveitic macular edema: treatment update. Curr Ophthalmol Rep. 2016;4(1):30\u20137.","journal-title":"Curr Ophthalmol Rep."},{"key":"209_CR3","unstructured":"National Institute for Health and Care Excellence (NICE) 2018. Final scope for the appraisal of fluocinolone acetonide ocular implant for treating recurrent non-infectious uveitis. https:\/\/www.nice.org.uk\/guidance\/gid-ta10368\/documents\/final-scope. Accessed 4 Jul 2019"},{"issue":"9","key":"209_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","volume":"88","author":"OM Durani","year":"2004","unstructured":"Durani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159\u201362.","journal-title":"Br J Ophthalmol"},{"key":"209_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667\u201380.","journal-title":"Drug Des Devel Ther."},{"issue":"5","key":"209_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","volume":"23","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705\u201317.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"209_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjo.78.1.1","volume":"78","author":"AD Dick","year":"1994","unstructured":"Dick AD. The treatment of chronic uveitic macular oedema. Br J Ophthalmol. 1994;78(1):1\u20132.","journal-title":"Br J Ophthalmol"},{"key":"209_CR8","doi-asserted-by":"crossref","unstructured":"Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage Proceedings of an expert panel roundtable discussion. Retina. 2006;26(8):1\u201316.","DOI":"10.1097\/01.iae.0000250601.15893.5f"},{"key":"209_CR9","doi-asserted-by":"publisher","first-page":"164692","DOI":"10.1155\/2014\/164692","volume":"2014","author":"M Cabrera","year":"2014","unstructured":"Cabrera M, Yeh S, Albini TA. Sustained-release corticosteroid options. J Ophthalmol. 2014;2014:164692.","journal-title":"J Ophthalmol."},{"issue":"4","key":"209_CR10","doi-asserted-by":"publisher","first-page":"626.e2","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626.e2\u2013635.e2.","journal-title":"Ophthalmology"},{"issue":"10","key":"209_CR11","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3\u00a0years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125\u201332.","journal-title":"Ophthalmology"},{"key":"209_CR12","unstructured":"ClinicalTrials.gov Identifier: NCT00344968. Fluocinolone acetonide implant compared to sham injection in patients with diabetic macular edema (FAME)."},{"key":"209_CR13","unstructured":"ClinicalTrials.gov Identifier: NCT01694186. Safety and efficacy of an injectable fluocinolone acetonide intravitreal insert."},{"issue":"3","key":"209_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583\u20137.","journal-title":"Ophthalmology"},{"key":"209_CR15","unstructured":"National Institute for Health and Care Excellence (NICE) guidelines [TA301]; 2013. https:\/\/www.nice.org.uk\/guidance\/TA301\/chapter\/1-Guidance. Accessed 4 July 2019"},{"key":"209_CR16","unstructured":"Alimera Sciences, Inc. ILUVIEN\u00ae (fluocinolone acetonide intravitreal implant) 0.19\u00a0mg for diabetic macular edema (DME)\u2014product overview. https:\/\/alimerasciences.com\/products\/iluvien-for-diabetic-macular-edema-dme\/. Accessed 4 July 2019"},{"key":"209_CR17","first-page":"265","volume":"11","author":"P Singh","year":"2018","unstructured":"Singh P, Chedid A, Deuchler SK, Kohnen T, M\u00fcller M, Koch FH. The efficacy and safety outcomes of the 0.19\u00a0mg fluocinolone acetonide implant after prior treatment with the 0.7\u00a0mg dexamethasone implant in patients with diabetic macular edema. Int Med Case Rep J. 2018;11:265\u20139.","journal-title":"Int Med Case Rep J."},{"issue":"6","key":"209_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","volume":"113","author":"GJ Jaffe","year":"2006","unstructured":"Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020\u20137.","journal-title":"Ophthalmology"},{"issue":"4","key":"209_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601\u201310.","journal-title":"Ophthalmology"},{"key":"209_CR20","unstructured":"Summary of Product Characteristics for ILUVIEN. https:\/\/www.medicines.org.uk\/emc\/medicine\/27636. Accessed 4 Jul 2019"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-019-00209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-019-00209-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-019-00209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T14:03:43Z","timestamp":1713362623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-019-00209-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1007\/s40123-019-00209-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}